methotrexate / Generic mfg. - LARVOL DELTA

Iguratimod in Autoimmune Diseases: Emerging Evidence for its Immunomodulatory and Therapeutic Role. (PubMed, Mediterr J Rheumatol) - "Traditional treatments include methotrexate and other DMARDs, but many patients experience inadequate responses or intolerable side effects...Iguratimod is a promising therapeutic option for the treatment of rheumatoid arthritis, Sjögren's disease, and ankylosing spondylitis. Further research is warranted to establish long-term efficacy and safety profiles and explore its potential in combination therapies for patients with inadequate responses to existing treatments."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Sjogren's Syndrome

Characteristics and Outcomes of Central Nervous System Multiple Myeloma (IMS 2026) - "Pts received a median of 4 (R:1-16) doses of IT therapy, 4/5 received thiotepa (2 in combination with methotrexate & cytarabine, & mercaptopurine respectively), & 1 received methotrexate alone. Systemic treatment included combination of proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, selinexor, & other novel therapeutics (1 received ciltacabtagene autoleucel (ciltacel), & another received talquetamab followed by teclistamab)...Pts with CSF clearance (2/5) had received ciltacel & VD-PACE, while 2/5 with radiographic response had received ciltacel & daratumumab-pomalidomide... CNS myeloma pts had a dismal prognosis. All pts relapsed within 30m of ASCT, pointing to functionally high-risk disease. This highlights the need for increased awareness for early identification & CNS directed therapies."

CNS Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study (ASH 2022) - "Twelve doses of prophylactic IT chemotherapy with alternating cytarabine and methotrexate were administered. Simultaneous ponatinib and blinatumomab is safe and effective in pts with newly diagnosed Ph+ ALL. This chemotherapy-free regimen results in high rates of CMR and NGS MRD negativity. Encouraging survival has been observed without the need for SCT."

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • ABL1 • CD19

Frontline Blinatumomab and Ponatinib in Ph+ Acute Lymphoblastic Leukemia: A Single-Center Real-World Experience (SOHO 2026) - "Interventions: After steroid prephase, dasatinib bridging was used (1 month) prior to ponatinib, until access approval...CNS prophylaxis included intrathecal triplet therapy with methotrexate, cytarabine, and dexamethasone, with a planned total of 15 administrations during ponatinib maintenance...In the CML blast phase patient, IGHV qPCR was not available; due to persistent BCR::ABL positivity, his treatment was supplemented with chemotherapy (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone), and he achieved a complete metabolic response and proceeded to transplant... Frontline blinatumomab plus ponatinib is a feasible chemotherapy-free strategy in Ph+ B-ALL, although limited by lack of first-line approval. Discordant MRD findings highlight the need for careful monitoring. Ongoing follow-up will determine durability of responses and whether allogeneic transplantation can be avoided in selected patients."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • IGH

PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY (EHA 2022) - "Twelve doses of prophylactic IT chemotherapy with alternating cytarabine and methotrexate were administered. Conclusion The chemotherapy-free regimen of simultaneous ponatinib and blinatumomab is safe and effective in pts with Ph+ ALL. For pts with ND Ph+ ALL, SCT does not appear to be needed in first remission."

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Cerebral Hemorrhage • Chronic Myeloid Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Movement Disorders • Oncology • Transplantation • ABL1

Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study. (ASCO 2023) - P1/2 | " Pts ≥18 years with R/R Ph-negative B- or T-cell ALL received mini-HCVD alternating with methotrexate and cytarabine for up to 8 cycles...Rituximab (if CD20+ B-ALL) and prophylactic IT chemotherapy x8 doses were given for the first 4 cycles. Pts with T-ALL received additional 2 cycles of nelarabine and peg-asparaginase during consolidation without Ven, and 2 cycles during maintenance. Maintenance with vincristine, prednisone and Ven was given for up to 2 years...Among the 18 B-ALL pts, 16 (89%) had received prior blinatumomab and 7 (39%) prior inotuzumab... The combination of low-intensity chemotherapy mini-HCVD with Ven in pts with R/R Ph-negative ALL was well-tolerated and resulted in a response rate of 67%. Further studies examining the role of Ven-based therapies in ALL are needed for newly diagnosed and R/R pts. Clinical trial information: NCT03808610."

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • CD20

A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY (EHA 2023) - "Twelve doses of prophylactic IT chemotherapy with alternating cytarabine and methotrexate were administered. The chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity. Encouraging duration of remission and survival has been observed without the need for SCT. Acute lymphoblastic leukemia, Clinical trial, Ph+ ALL"

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Transplantation • Vascular Neurology • ABL1

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study (ASH 2022) - "Twelve doses of prophylactic intrathecal chemotherapy with alternating cytarabine and methotrexate were administered. The chemotherapy-free combination of ponatinib and blinatumomab is a safe and effective regimen in both R/R Ph+ ALL and CML-LBP. High rates of deep molecular response were observed in R/R Ph+ ALL. However, CMR rates were relatively low in pts with CML-LBP, suggesting that alternative approaches should be considered in these pts."

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Movement Disorders • Neutropenia • Oncology • Thrombosis • Transplantation • Venous Thromboembolism • ABL1 • CD19

Comparative Efficacy and Safety of Front-line Regimens for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Systematic Review and Network Meta-Analysis (SOHO 2026) - " We searched PubMed, Embase, and 2024–2026 conference abstracts for prospective trials of frontline TKIs (imatinib, dasatinib, ponatinib) with chemotherapy or blinatumomab. Ponatinib plus blinatumomab is the most effective front-line regimen for Ph–positive ALL, offering superior molecular depth and survival. These findings support chemotherapyfree protocols as the new standard of care and suggest that deep molecular responses may safely allow the omission of front-line SCT. CMR: complete molecular response, CrI: credible interval, EFS: event-free survival, HR: hazard ratio, hyper-CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, MRD: measurable residual disease, OS: overall survival, SCT: stem cell transplant, SUCRA: surface under the cumulative ranking curve."

Retrospective data • Review • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Upadacitinib-Methotrexate Combination Therapy for Refractory Atopic Dermatitis: A Case Series of a Novel Therapeutic Approach. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma. (PubMed, Curr Opin Oncol) - "Future therapeutic progress in PCNSL should prioritize prediction, early detection, and prevention of neurotoxicity alongside disease control."

Journal • CNS Lymphoma • Cognitive Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

Antioxidant and Bone Regeneration Properties of a Hydrogel Loaded with Gallic Acid-Functionalized MgO Nanoparticles to Treat Rheumatoid Arthritis. (PubMed, ACS Biomater Sci Eng) - "Methotrexate is used to treat RA, but it is associated with side effects, like nephrotoxicity and immunosuppression, and there is a lack of drug-free strategies to target the progression of disease and tissue regeneration...We report, for the first time, gallic acid-grafted MgO nanoparticles that harness intrinsic antioxidant and apoptotic activity for RA therapy. In summary, we have developed a drug-free, multipotent system for alleviating RA by suppressing inflammation and promoting tissue preservation."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Obeticholic acid attenuates complete freund's adjuvant-induced arthritis in rats through FXR-mediated modulation of TGF-β/TAK1/MKK3/p38 MAPK signaling, inflammation, and oxidative stress. (PubMed, Inflammopharmacology) - "Rats were allocated into nine groups: normal control, OCA control, arthritic control, arthritic rats treated with OCA at 2.5 or 5 or 10 mg/kg, methotrexate-treated arthritic rats, F44-A13-treated arthritic rats, and arthritic rats co-treated with F44-A13 and OCA. Histopathological assessment confirmed attenuation of synovial inflammation, cartilage damage, and proteoglycan loss. Co-administration of the FXR antagonist F44-A13 markedly blunted the protective effects of obeticholic acid.These findings indicate that OCA attenuates CFA-induced experimental arthritis and that these effects are associated with FXR-related changes in TGF-β/TAK1/MKK3/p38 MAPK gene expression, inflammatory mediators, and oxidative stress."

Journal • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology • CAT • CRP • IFNG • IL1B • IL6 • MAP2K3 • TGFB1 • TNFA

Enteric NK/T Cell Lymphoma-induced Recurrent Perforation in the Intestine: A Case Report. (PubMed, Ann Ital Chir) - "Primary intestinal ENKTL is a rare and highly aggressive subtype of non-Hodgkin lymphoma, whose non-specific clinical and imaging manifestations pose major challenges for early diagnosis, which may lead to delayed treatment and unfavorable prognosis. This disease should be included in the core differential diagnosis for young patients, especially Asian populations, presenting with unexplained gastrointestinal perforation. Repeated deep tissue biopsy, EBER detection combined with comprehensive imaging evaluation are essential for early definitive diagnosis, and timely surgical intervention combined with standardized systemic chemotherapy can effectively improve the clinical outcomes of affected patients."

Journal • Epstein-Barr Virus Infections • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • T Cell Non-Hodgkin Lymphoma • CD2 • NCAM1

Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study). (PubMed, Br J Clin Pharmacol) - "SC IFX in IBD patients maintained equivalent drug exposure with higher trough levels, reduced time burden and stable quality-of-life, independent of concomitant immunosuppressants."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology

First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes. (PubMed, Rheumatology (Oxford)) - "Initial therapy with b/tsDMARDs in combination with methotrexate is associated with higher remission rates than methotrexate alone in patients with early RA. As monotherapy, higher remission rates were observed for JAK inhibitors and tocilizumab."

Journal • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Septic arthritis mimic unmasked: inflammatory bowel disease-associated arthritis in a patient with a learning disability. (PubMed, BMJ Case Rep) - "Colonoscopy and biopsy findings were compatible with Crohn's disease. Antibiotics were stopped and prednisone plus methotrexate, then infliximab, led to clinical and laboratory improvement with no active bowel inflammation on follow-up MR enterography."

Journal • Cognitive Disorders • Crohn's disease • Dermatology • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Rheumatology

CLINICAL PRESENTATION AND SOCIAL IMPLICATIONS OF COEXISTING SARCOIDOSIS AND SILICOSIS IN COAL MINERS (ERS 2026) - "All pts were diagnosed with Si and comorbid pulmonary S. Combined therapy (methotrexate 10 mg + folic acid) resulted in clinical improvement, reflected in HRCT, ACE, and CRP dynamics. Pts exposed to SiO2 are at high risk of developing both Si and S. Histological confirmation is vital for diagnosis. Recognizing S as an occupational disease is crucial to provide workers with access to mandatory compensation and social benefits."

Clinical • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • IFNG

Tumour-derived microparticles obtained through microwave irradiation induce immunogenic cell death in lung adenocarcinoma (ERS 2026) - "We show that they can efficiently deliver methotrexate to tumours, synergistically boosting the efficacy of PD-L1 blockade. This MW-TMP development strategy is simpler, more efficient and safer than traditional UV-TMP methods."

Immunogenic cell death • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HMGB1

The risk of interstitial lung diseases in patients with psoriasis and psoriatic arthritis (ERS 2026) - "Methotrexate use was associated with an increased risk of ILD in patients with psoriasis (HR 2.03 (1.44-2.85)), but not in patients with PsA (HR 1.38 (0.84-2.26)). In this large nationwide study, ILD was more prevalent in patients with psoriasis and PsA than in matched reference populations. The risk of developing ILD was increased in psoriasis and even higher in PsA."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies

Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Understanding and Insights from a UK Clinician Survey (ERS 2026) - "This survey shows wide variation in RA‑ILD service provision,MDT access,screening,and diagnostic pathways across the NHS.HRCT access is generally efficient,but delays in PFT and limited structured review capacity lead to inconsistent monitoring.The findings highlight the need for national guidance, improved service integration and more consistent RA‑ILD management."

Clinical • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Methotrexate Versus Corticosteroids as First-line Treatment for Pulmonary Sarcoidosis: Systematic Review and Meta-analysis (ERS 2026) - "Methotrexate was noninferior to Prednisone for Forced Vital Capacity (FVC) improvement (−1.17 pp; 95% CI −4.27 to 1.93). Methotrexate shows comparable efficacy with lower treatment resistance, supporting consideration as first-line alternative."

Retrospective data • Review • CNS Disorders • Immunology • Insomnia • Sarcoidosis • Sleep Disorder

Pediatric Sarcoidosis: Single-Center Experience, Clinical, Radiological Findings and Long Term Prognosis of Patients (ERS 2026) - "Methotrexate (MTX) was used in 7 patients (41.2%) as a steroid-sparing or rescue agent... Pediatric sarcoidosis presents with a wide clinical spectrum. Extrapulmonary involvement necessitates careful screening.High biopsy confirmation rates and the successful use of MTX highlight the importance of a multidisciplinary approach and individualized therapy for long-term management."

Clinical • Cough • Immunology • Pediatrics • Respiratory Diseases • Sarcoidosis

REmission in pulmonary Sarcoidosis using Early Treatment with TNF-alpha inhibitors (RESET-TNF study) (ERS 2026) - "Methotrexate (MTX) was found non-inferior to prednisone as first-line treatment in pulmonary sarcoidosis with regard to forced vital capacity (FVC) at week 24, but with different side effects...Methods RESET-TNF is an investigator-initiated, open-label randomized controlled trial designed to evaluate whether the TNF-α inhibitor XTMAB-16 is superior to MTX in pulmonary sarcoidosis...Furthermore, we will investigate mechanistic impact through baseline blood biomarkers and in-vitro granuloma formation after treatment. Discussion The RESET-TNF study will be the first study to assess if first-line treatment with anti-TNF-α is superior to conventional treatment in pulmonary sarcoidosis, and provide novel insights into the potential for immune system resetting."

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • Sarcoidosis

Online home monitoring of symptoms in patients with sarcoidosis using visual analogue scales: an analysis of the PREDMETH trial (ERS 2026) - "Conclusions Symptoms significantly improved over time after start of methotrexate, whereas only fatigue improved in patients on prednisone. Weekly completion of online VAS is feasible and yields detailed insights in symptom trajectories and time to improvement after start of treatment."

Clinical • Cough • Immunology • Pulmonary Disease • Respiratory Diseases • Sarcoidosis